Jeffrey Rhodes left the role of Director at LifeStance Health Group, Inc. As of November 6, 2026, LifeStance Health Group, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 7, 2026 to October 16, 2026, naming 2 appointments and 1 departure (Form 8-K, July 7, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like LifeStance Health Group, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
LifeStance Health Group, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-07 to 2026-10-16. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as LifeStance Health Group, Inc. files it.
Also on the record for LifeStance Health Group, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 5, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 10.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by TPG GP A, LLC | 25.7% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G/A, by Summit Partners, L.P. | 6.1% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 8.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by TPG GP A, LLC | 29.3% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Summit Partners, L.P. | 7.49% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Summit Partners, L.P. | 8.62% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 10.1% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 10% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs LifeStance Health Group, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on LifeStance Health Group, Inc. and the records around it.
LifeStance Health Group, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Summit Partners, L.P. also filed stake reports on 1 other company: Klaviyo, Inc. (Nov 2025)
- TPG GP A, LLC also filed stake reports on 15 other companies: Allogene Therapeutics, Inc. (Sep 2026), TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch LifeStance Health Group, Inc.
Get an email when LifeStance Health Group, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on LifeStance Health Group, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on LifeStance Health Group, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on LifeStance Health Group, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Reported | not named in the filing | 8-K, 2026-10-16 | ||
| 2026-07-07 | Out | Director | 8-K, 2026-07-07 | ||
| 2026-07-07 | In | Director | 8-K, 2026-07-07 | ||
| 2026-07-07 | In | 8-K, 2026-07-07 |
Who leads LifeStance Health Group, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Jeffrey Rhodes, departure reported (filed 2026-07-07). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on LifeStance Health Group, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at LifeStance Health Group, Inc., with the record behind each one.
Find candidates like Director at LifeStance Health Group, Inc.Every change, in the filing's words
Reported
On October 14, 2026, Teresa DeLuca, M.D., notified the LifeStance Health Group, Inc. (the "Company") board of directors (the "Board") of her resignation from the Board and all of its committees, effective as of December 31, 2026.
- The resignation is not a result of any disagreement between Dr. DeLuca and the Company.
Departing: Jeffrey Rhodes, Director
On July 2, 2026, Jeffrey Rhodes notified the LifeStance Health Group, Inc. (the "Company") board of directors (the "Board") of his resignation from the Board and all of its committees, effective immediately.
Appointed: Thurman Justice, Director
In connection with Mr. Rhodes' resignation and to fill vacancies on the Board, on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.
Appointed: Safwan Shabab
Mr. Shabab was appointed to the Board in accordance with and pursuant to a Stockholder's Agreement, dated as of June 9, 2021, by and between the Company and certain of its stockholders, which is filed as Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 15, 2021.
- The resignation is not a result of any disagreement between Mr. Rhodes and the Company.
- Mr. Justice and Ms. Goltermann were appointed as Class II directors and will initially serve until the Company's 2029 annual meeting of stockholders and Mr. Shabab was appointed as a Class III director and will initially serve until the Company's 2027 meeting of stockholders.
- Mr. Justice will serve as a member of the audit committee and the quality and compliance committee of the Board, Ms. Goltermann will serve as a member of the compensation committee and nominating and governance committee of the Board and Mr. Shabab will serve as a member of the nomination and governance committee of the Board.
- In connection with their appointments, pursuant to the Company's 2021 Equity Incentive Plan, Mr. Justice and Ms. Goltermann each received an initial award of 35,492 restricted stock units that will vest according to the terms of a time-and performance-based restricted stock unit agreement, subject to Mr. Justice and Ms. Goltermann's continued service on the Board.
Tools for this story
Each opens in a new tab, filled in for LifeStance Health Group, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.